A. Karim Kader, MD, PhD, presented “Impact of PCa Risk on PCa Early Detection” during the 33rd International Prostate Cancer Update on January 23, 2023, in Vail, Colorado.
How to cite: Kader, A. Karim. “Impact of PCa Risk on PCa Early Detection.” January 23, 2023. Accessed Nov 2024. https://grandroundsinurology.com/impact-of-pca-risk-on-pca-early-detection/
Impact of PCa Risk on PCa Early Detection – Summary
A. Karim Kader, MD, PhD, Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, discusses the dilemma of prostate cancer that stems from that while all men do not need to be diagnosed/screened, prostate cancer can be cured when caught early, but it remains the second most common cause of male cancer deaths. Dr. Kader illustrates the positive impact that prostate-specific antigen (PSA) screening has made historically, but points out inefficiencies. Out of 1400 men screened, 48 required treatment, with one life saved. Dr. Kader cites another study that demonstrated no survival benefit to prostate cancer screening and explains that he is an advocate of risk-adapted screening, suggesting that men who need to be screened are those who test as high-risk on a germ-line polygenic risk score. He cites interim results from the IMPACT study that show BRCA2 carriers had an increased risk of clinically significant disease. Dr. Kader displays data on the impact of polygenic risk score on prostate cancer outcomes, explaining that risk factors and polygenic risk score are additive predictors of those outcomes. Finally, Dr. Kader outlines his take-home messages: Broad-based prostate cancer screening has not yielded mortality benefits; metastasis-free survival is an important outcome that should be considered as the primary outcome of screening studies; risk-adapted screening focusing on men with above-average risk will likely yield superior trial results; and men with a low baseline PSA and/or men with low polygenic risk scores should consider limiting PSA-based prostate cancer screening.
About The 33rd Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 33rd iteration of the meeting occurred January 22-25, 2023 in Vail, Colorado. To view more educational presentations from IPCU 33, visit our collection page.
ABOUT THE AUTHOR
A. Karim Kader, MD, PhD, is a board-certified urologist who specializes in screening, detecting, treating and preventing prostate cancer. He has successfully a genetic test to predict lifetime risk of developing prostate cancer. As a Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, Dr. Kader instructs medical students, residents and fellows at UC San Diego School of Medicine. His current research interests include artificial intelligence in healthcare and the use of augmented reality and enhanced imaging techniques for education and improved surgical outcomes. Dr. Kader completed a Fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston and a Residency in Urology at the University of Toronto in Ontario, Canada. He earned his medical degree and doctoral degree from the University of British Columbia in Vancouver, British Columbia. Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries focused on the early detection and prevention of prostate cancer in addition to device patents for prostate cancer treatment. He is the principal investigator in numerous clinical research projects and has published extensively.
